© 2024 Access Intelligence, LLC - All Rights Reserved
PAGES
CATEGORIES
Current POWER Magazine Issue
We are first in your inbox with the most important news in the industry?keeping you smarter and one-step ahead in this ever-changing and competitive market.
Start your free subscription) 2020 Access Intelligence, LLC - All Rights Reserved
This white paper outlines the most common reasons the FDA has issued Form 483 Inspectional Observations since the beginning of FY 2016 through the present date and shows how an Enterprise Quality Management System (EQMS) can help pharmaceutical companies avoid running afoul of the FDA and other like-minded regulatory bodies.
The U.S. Food and Drug Administration (FDA) issues Form 483 Inspectional Observations or warning letters when communicating to a pharmaceutical company that its quality practices are not in compliance with regulatory standards. Most of these observations and warnings are due to some form of the following infractions:
Offered Free by: MasterControl Inc.
See All Resources from: MasterControl Inc.